Modality
Multispecific
MOA
JAK1/2i
Target
JAK2
Pathway
NF-κB
NBNSCLCHS
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ May 2030
Phase 1Current
NCT08425354
2,719 pts·NB
2020-12→2025-11·Recruiting
NCT04855461
660 pts·NSCLC
2023-07→2030-05·Not yet recruiting
3,379 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-244mo agoInterim· NB
2030-05-034.1y awayInterim· NSCLC
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2025-11-24 · 4mo ago
NB
Interim
2030-05-03 · 4.1y away
NSCLC
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08425354 | Phase 1 | NB | Recruiting | 2719 | MRD |
| NCT04855461 | Phase 1 | NSCLC | Not yet recr... | 660 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |